CEDO
27.7.2021 09:02:17 CEST | Business Wire | Press release
Cedo , one of Europe’s largest manufacturers of household waste bags made with recycled plastics, has made its first major leap towards becoming a climate neutral business, powering its UK factory in Telford and offices in Paris and Mönchengladbach with 100 per cent renewable energy. Its UK business, based in Shropshire, has also achieved its target of sending zero manufacturing waste to landfill.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210727005178/en/
More than 23 per cent of Cedo’s global operations now use 100 per cent renewable energy, with suppliers including green energy provider Total and PGE S.A in Poland. Cedo’s remaining factories in Vietnam, Poland and the Netherlands are also on target to achieve climate neutrality over the next few years.
“Cedo’s aim is to become a climate neutral business worldwide by 2030. By increasing our use of renewable energy year-on-year while focusing our efforts on achieving zero manufacturing waste to landfill, we are making rapid progress towards our goal,” said Rik De Vos, CEO of Cedo. “Our next ambition is to continue to pursue a more circular approach in our stewardship of raw materials, while creating a sustainable business that is no longer reliant on fossil fuel-based virgin polymers.
“In the very near future every Cedo non-food product will be fully recycled and recyclable. We believe that keeping our homes clean, safe and tidy in an environmentally friendly way should be as simple as putting out the bins,” said De Vos.
Established in 1965, Cedo is one of the world’s leading plastics recycling businesses, specialising in the recycling of post-consumer household packaging waste such as plastic packaging and clingfilm. Every year, the business uses more than 80,000 tons of recycled plastic to make over 4 billion refuse sacks and bin liners from factories based in Poland, the Netherlands, Vietnam and the UK, operating one of the largest flexible plastic film recycling centres in Europe.
Cedo products from bin liners to food wrap and latex gloves can be found in supermarkets and retailers in 34 countries. In the UK, 93% of the plastic used by Cedo to manufacture non-food products is from recycled sources.
As we approach Earth Overshoot Day on 29 July, Cedo is one quarter of the way to achieving its 100 per cent renewable energy goal, which will see it becoming a climate neutral business by 2030.
- Ends –
About Cedo
Established in 1965, Cedo is one of Europe's largest and most sustainable suppliers of refuse sacks made from recycled plastics, as well as other consumer household products designed to protect and store food. For more than thirty years it has led the development of recycling mixed plastic film recovered from households to give more plastic a second life, creating 100% recycled and 100% recyclable products designed to keep European households, workplaces and leisure spaces clean, healthy and safe.
As founding signatories to both the Ellen MacArthur Foundation’s New Plastics Economy Global Commitments and the European Plastics Pact, Cedo is working with partners including NGO The Plastic Bank to create new solutions and interventions to address the challenges of building a new plastics economy.
For two years, Cedo has been recognised by the Sunday Times top track 250 (fast growing medium sized privately owned business). By 2030 the business will be climate neutral across its global operations.
For more information please visit cedo.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210727005178/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Industrial Decarbonization: Calderion, WenCo and Terravent Invest in Graforce to Scale Plasma Pyrolysis Globally25.2.2026 08:07:00 CET | Press release
The investor consortium comprising the Paris-based Next Generation Fuels Industrial & Technological fund Calderion (Audacia), alongside infrastructure developer Terravent and WenCo Family Office, announces the closing of a strategic double-digit million-euro financing round for Berlin-based Graforce GmbH. The investment is dedicated to the industrial scale-up of Graforce’s proprietary plasma pyrolysis technology, addressing the growing global demand for cost-efficient low-carbon hydrogen, syngas, and carbon removal solutions that are compatible with existing industrial infrastructures. Disruptive alternative to conventional processes Graforce’s technology aims at replacing CO₂-intensive legacy routes such as steam reforming and classical gasification. By applying plasma to methane, biogas, flare gas, and landfill gas, the process converts these streams into their valuable molecular components instead of emitting them. The result is a high-efficiency production of clean hydrogen and syn
Mevion Medical Systems Announces CE Marking of the MEVION S250-FIT™ Proton Therapy System, Expanding Global Access to Compact Proton Therapy25.2.2026 08:00:00 CET | Press release
CE Marking enables marketing and clinical use of the world’s first and only LINAC vault-ready proton therapy system across the European Union Mevion Medical Systems, the global leader in compact proton therapy, today announced that the MEVION S250-FIT Proton Therapy System has successfully completed the conformity assessment process and has received CE Marking under Regulation (EU) 2017/745 (EU MDR). This regulatory milestone enables the marketing, sale, and clinical use of the MEVION S250-FIT system throughout the European Union, building on the system’s existing U.S. FDA 510(k) clearance granted in September 2025. The MEVION S250-FIT is the first and only proton therapy system designed to fit into a standard radiation therapy vault. By enabling cancer centers to use their existing infrastructure, the MEVION S250-FIT dramatically reduces the cost, complexity, and timeline traditionally associated with proton therapy adoption. This opens a new pathway for hospitals and cancer centers a
Bureau Veritas:Sector-Leading Organic Revenue Growth of 6.5% in FY 202525.2.2026 07:30:00 CET | Press release
Strong margin improvement to 16.3% in FY 2025Positive growth outlook with continued margin expansion in 2026New EUR 200 million share buyback Bureau Veritas (BOURSE:BVI): 2025 key figures1 › Full-year revenue of EUR 6,466.4 million, up 6.5% organically (with 6.3% organic growth in Q4). At constant currency, the growth was up 7.3% year-on-year and up 3.6% on a reported basis, › Adjusted operating profit of EUR 1,052.9 million, up 5.7% versus EUR 996.2 million in FY 2024, representing an adjusted operating margin of 16.3%, up 32 basis points year-on-year and up 51 basis points at constant currency, › Operating profit of EUR 992.4 million, up 6.3% versus EUR 933.4 million in FY 2024, › Adjusted net profit of EUR 631.4 million, up 1.7% versus EUR 620.7 million in FY 2024, › Adjusted EPS stood at EUR 1.42 in 2025, with a 2.8% increase versus FY 2024 (EUR 1.38 per share) and up 9.2% at constant currency, › Attributable net profit of EUR 588.0 million, up 3.3% versus EUR 569.4 million in FY 2
Galderma Announces Triple Approval of New State-of-the-Art Restylane® Syringe in the EU, the U.S., and Canada, Reaffirming the Company’s Position at the Forefront of Injectable Aesthetics25.2.2026 07:00:00 CET | Press release
Regulatory authorities in the European Union (EU), the United States (U.S.), and Canada have approved a new state-of-the-art Restylane®syringe for use with a range of Restylane NASHA® lidocaine products in multiple indications in the face and in the hands1-3 Developed in collaboration with aesthetic practitioners, its innovative ergonomic design features a cushioned finger grip and thumb rest, to improve practitioner experience through better injection comfort and control, helping them deliver consistently premium results 4-7 The syringe’s carton packaging is the first in the industry to be made from 100% recyclable paper, and reaffirms Galderma’s commitment to sustainability and environmental responsibility 8 These approvals demonstrate Galderma’s strong heritage in Injectable Aesthetics, and its commitment to continuing to drive innovation in the field Galderma (SIX: GALD), today announced that regulatory authorities in the EU, the U.S., and Canada have approved a new state-of-the-ar
Azafaros Announces Publication of Preclinical Efficacy Data with Nizubaglustat in GM2 Gangliosidosis25.2.2026 07:00:00 CET | Press release
Preclinical proof-of-concept data in GM2 gangliosidosis demonstrated survival benefit, functional improvement and target engagementResults are published in the 7 January issue of the Journal of Inherited Metabolic DiseaseNizubaglustat is currently in Phase 3 registrational studies in GM1/GM2 gangliosidoses and Niemann-Pick type C disease (NPC) Azafaros, a company aiming to become a leader in lysosomal storage disorders (LSDs), focused on addressing especially neurological symptoms, today announced the publication of proof-of-concept preclinical data with its lead product, nizubaglustat, in GM2 gangliosidosis. The data, published in the 7 January issue of the Journal of Inherited Metabolic Disease in collaboration with the laboratory of Dr. Jagdeep Walia, Department of Pediatrics, Queen's University, Kingston, Canada, reinforce nizubaglustat’s potential to address unmet needs in rare LSDs and build on existing preclinical and clinical evidence. The preclinical study tested nizubaglustat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom